GlassScriptPhysician profile
Harvey J Hotchner
NPI 1932299054
$19,799.26
in general payments reported to CMS, 2019-2025
59 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,482 · 2020: $2,348 · 2021: $3,381 · 2022: $3,700 · 2023: $1,777 · 2024: $3,854 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,845 · Food and Beverage: $2,464 · Travel and Lodging: $379 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,845.00 |
| Food and Beverage | $2,464.27 |
| Travel and Lodging | $378.99 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $2,876.07 | 2021-2024 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $2,263.06 | 2019-2024 | Opdivo, Eliquis |
| Janssen Biotech, INC. | $1,825.13 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $1,212.27 | 2019-2024 | Imfinzi, Enhertu |
| Seagen INC. | $1,153.82 | 2019-2023 | Adcetris, Padcev |
| Incyte Corporation | $1,008.67 | 2019-2024 | Jakafi |
| Pfizer INC. | $811.16 | 2019-2024 | |
| Genentech USA, INC. | $687.99 | 2019-2023 | Gazyva, Venclexta, Lunsumio |
| Novartis Pharmaceuticals Corporation | $613.02 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $556.18 | 2019-2023 | Keytruda, Lynparza |
| Amgen INC. | $547.37 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Genzyme Corporation | $500.29 | 2019-2023 | |
| Celgene Corporation | $466.82 | 2019-2023 | Pomalyst, Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $448.40 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $410.35 | 2019-2023 | Xospata |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Hotchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.